LEGISLATIVE HISTORY—S. 164:  CONGRESSIONAL RECORD, Vol. 167 (2021):  Mar. 3, considered and passed Senate.  Apr. 14, considered and passed House.  Æ  PUBLIC LAW 117–8—APR. 23, 2021  135 STAT. 255  ‘‘(3) FORMAT.—The educational materials provided under  paragraph (1) may be—  ‘‘(A) in formats such as webinars, continuing education  modules, videos, fact sheets, infographics, stakeholder tool- kits, or other formats as appropriate and applicable; and  ‘‘(B) tailored for the unique needs of health care pro- viders, patients, caregivers, and other audiences, as the  Secretary determines appropriate.  ‘‘(4) OTHER INFORMATION.—In addition to the information  described in paragraph (2), the Secretary shall continue to  publish—  ‘‘(A) the action package of each biological product  licensed under subsection (a) or (k) of section 351; or  ‘‘(B) the summary review of each biological product  licensed under subsection (a) or (k) of section 351.  ‘‘(5) CONFIDENTIAL AND TRADE SECRET INFORMATION.—This  subsection does not authorize the disclosure of any trade secret,  confidential commercial or financial information, or other  matter described in section 552(b) of title 5.  ‘‘(b) CONTINUING EDUCATION.—The Secretary shall advance  education and awareness among health care providers regarding  biological products, including biosimilar biological products and  interchangeable biosimilar biological products, as appropriate,  including by developing or improving continuing education pro- grams that advance the education of such providers on the pre- scribing of, and relevant clinical considerations with respect to,  biological products, including biosimilar biological products and  interchangeable biosimilar biological products.’’.  Approved April 23, 2021. 